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Introduction: Activation of the inflammasome has been implicated in the pathology of various autoinflammatory
and autoimmune diseases. While the NLRP3 inflammasome has been linked to arthritis progression, little is known
about its synovial regulation or contribution to joint histopathology. Regulators of inflammation activation, such as
interleukin (IL)-10, may have the potential to limit the inflammasome-driven arthritic disease course and associated
structural damage. Hence, we used IL-10-deficient (IL-10KO) mice to assess NLRP3 inflammasome-driven arthritic
pathology.
Methods: Antigen-induced arthritis (AIA) was established in IL-10KO mice and wild-type controls. Using histological
and radiographic approaches together with quantitative real-time PCR of synovial mRNA studies, we explored the
regulation of inflammasome components. These were combined with selective blocking agents and ex vivo
investigative studies in osteoclast differentiation assays.
Results: In AIA, IL-10KO mice display severe disease with increased histological and radiographic joint scores. Here,
focal bone erosions were associated with increased tartrate-resistant acid phosphatase (TRAP)-positive cells and a
localized expression of IL-1β. When compared to controls, IL-10KO synovium showed increased expression of Il1b, Il33
and NLRP3 inflammasome components. Synovial Nlrp3 and Casp1 expression further correlated with Acp5 (encoding
TRAP), while neutralization of IL-10 receptor signaling in control mice caused increased expression of Nlrp3 and Casp1.
In ex vivo osteoclast differentiation assays, addition of exogenous IL-10 or selective blockade of the NLRP3
inflammasome inhibited osteoclastogenesis.
Conclusions: These data provide a link between IL-10, synovial regulation of the NLRP3 inflammasome and the degree
of bone erosions observed in inflammatory arthritis.Introduction
As new biologics enter the clinical arena and advances in
synovial histopathology identify divergent mechanisms of
arthritis progression, it is essential to understand how the
cytokine network governs the pattern of synovial inflam-
mation [1,2]. Innate sensing mechanisms involving pattern
recognition receptors are increasingly implicated in auto-
immunity and promote cytokine responses associated with* Correspondence: jonessa@cf.ac.uk
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unless otherwise stated.rheumatoid arthritis. Although these pathways represent
promising therapeutic targets, further investigation is re-
quired to understand the expression and functional contri-
bution of pattern recognition receptors in autoimmunity.
Pattern recognition receptors were initially character-
ized as sensors of microbial products of bacterial, fungal
or viral infection. These include the Toll-like receptors
(TLR); nucleotide-binding domain and leucine-rich repeat
containing receptors (NLR), Rig-I-like receptors (RLR)
and C-type lectins [3,4]. Activation of these receptors pro-
motes the inflammatory regulation of various interleukins,
tumour necrosis family members and type-1 interferonsal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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which shape the adaptive immune response to chronic
disease, allergy, cancer and infection. As a consequence,
various processes have evolved to protect against the pro-
longed activation of these receptors. For example, inter-
leukin (IL)-10 limits the duration and intensity of their
signaling in myeloid cells [5,6]. Here, IL-10 inhibits pat-
tern recognition receptor signaling through mechanisms,
which include downregulation of MyD88 expression [7],
and the ubiquitination and subsequent degradation of
MyD88-dependent signaling molecules such as TRAF6
[8]. In experimental models of inflammatory arthritis, IL-
10 is protective and mice deficient in IL-10 show exacer-
bated joint inflammation [9,10]. These data are consistent
with the characterization of IL-10 as a cytokine synthesis
inhibitory factor, which acts as an immunomodulatory
cytokine affecting both innate and cellular immunity
[11,12]. For example, IL-10 inhibits nuclear factor kappa B
(NF-κB) signaling in response to TLR agonists to block
expression of certain proinflammatory mediators associ-
ated with arthritis progression. Interleukin-10 is abun-
dantly expressed in synovial fluids of RA patients and has
been linked with the control of bone resorption through
inhibition of osteoclastogenesis in vitro [13-15].
While IL-10 is renowned for its ability to inhibit TLR
signaling, its impact on innate sensing receptors, including
the NLR family, is less documented. Here, caspase 1 activ-
ity is essential for the processing of cytokine precursors
(for example, pro-IL-1β, pro-IL-18 and potentially pro-IL-
33) into functionally active mature forms [16]. Activation
of caspase 1 by the NLR family member NLRP3, acting in
association with its adaptor protein ASC, leads to the
secretion of IL-1β and IL-18 [16]. Each of these cytokines
affect arthritis progression [17,18], which suggests that in-
nate sensing complexes (termed the inflammasome) must
be regulated during the course of disease. Various particu-
late and crystalline agonists activate the NLRP3 inflamma-
some. For example, monosodium urate crystals and
calcium pyrophosphate dihydrate crystals trigger arthritis
symptoms in inflammatory forms of gout and pseudogout
[19-21], while basic calcium phosphate (hydroxyapatite)
crystals are seen in 70% of osteoarthritis (OA) cases
[22,23]. A role for the NLRP3 inflammasome in arthritic
disease is illustrated by several in vitro studies, which
show that crystals from the joints of OA patients and
basic calcium phosphate crystals induce IL-1β production
by macrophages [24,25]. Also, a recent report shows that
there is modulation of the NLRP3 inflammasome in
peripheral blood mononuclear cells in RA patients and
that single nucleotide polymorphisms (SNPs) in NLRP3
are associated with disease severity [26]. However, little is
known about the regulation and activation of inflamma-
some components in inflammatory arthritis. We now
show that the exacerbated joint pathology seen in IL-10KO mice during antigen-induced arthritis (AIA) is asso-
ciated with increased synovial expression of NLRP3
inflammasome components and a localized expression of
IL-1β at sites of focal bone erosions. Our data supports a
role for IL-10 as a negative regulator of the inflammasome
and highlights a role for the inflammasome in osteoclasto-
genesis during inflammatory arthritis.
Materials and methods
Mouse strains
Inbred C57BL/6 mouse strains from The Jackson
Laboratory (Bar Harbor, ME, USA) were bred and main-
tained in-house under high barrier and pathogen-free
conditions. All animal studies were performed in the
United Kingdom. Experiments were performed on eight-
to twelve-week-old male mice in accordance with UK
Home Office Project License PPL-30/2361 and 30/2928.
The ethical approval of these licenses covers all aspects
of the study and all experiments conducted.
Induction of murine AIA
Mice were immunized (subcutaneous (s.c.)) with an emul-
sion containing 1 mg/ml methylated bovine serum albu-
min (mBSA) in phosphate-buffered saline (PBS) and
Freud’s complete adjuvant (CFA) (Sigma-Aldrich, St Louis,
MO, USA). Concurrently, mice were injected (intraperito-
neal (i.p.)) with 200 ng of heat-inactivated Bordetella per-
tussis toxin adjuvant (Sigma-Aldrich, Poole, UK). The
immune response was boosted one week later with a sec-
ond injection (s.c.) of mBSA emulsified in CFA. Arthritis
was induced two weeks later with an intra-articular (i.a.)
injection of 10 μl of mBSA (10 mg/ml) into the right knee
joint. Arthritis progression was monitored using a mi-
crometer to measure changes in knee joint swelling.
Radiology
A Kodak in vivo Imaging System FX was used to take
radiographs of the mouse knee joints. Both arthritic (right)
and non-arthritic joints (left) were compared. Radio-
graphic scores were independently assigned by an ortho-
pedic registrar and based on visible bone erosions (0;
normal, 1; mild, 2; moderate, 3; severe).
Histology
Joints were fixed in neutral-buffered formalin saline, decal-
cified with formic acid at 4°C and embedded in paraffin.
Midsagittal sections (8 μm) were stained with haematoxy-
lin, safranin-O and Fast Green. Two independent observers
scored histology sections for subsynovial inflammation (0 =
normal, to 5 = ablation of adipose tissue due to leukocyte
infiltrate), synovial exudate (0 = normal, to 3 = substantial
number of cells with large fibrin deposits), synovial hyper-
plasia (0 = normal 1 to 3 cells thick, to 3 = over three layers
thick with overgrowth onto joint surfaces with evidence of
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3 = destruction of a significant part of the bone). Cartilage
integrity was determined in histological sections using a
Mankin scoring system. Two independent observers evalu-
ated cartilage irregularity and cleft formation (0 = normal,
to 6 = complete disorganization of glycoproteins with clefts
into the cartilage), cellularity (0 = normal, to 3 = hypocellu-
larity), proteoglycan depletion (0 = normal, to 4 = complete
proteoglycan degradation with no dye apparent) and tide-
mark integrity (0 = intact, to 1 = tidemark crossed by blood
vessels). The total sum of these scores resulted in a max-
imum score of 14. For detection of tartrate-resistant acid
phosphatase (TRAP) activity, slides were rehydrated after
decalcification, incubated with TRAP staining solution
(0.2 M acetate buffer, 50 mM sodium tartrate, 0.5 mg/ml
naphthol AS-MX phosphate, 1.1 mg/ml Fast Red Violet LB
salt) and counterstained with haematoxylin.
Immunohistochemistry
Antigen retrieval was performed on paraffin-embedded
sections using either trypsin (0.1%) for 30 mins at 37°C, or
10 mM citrate buffer (pH 6) for 40 mins at 95°C. En-
dogenous peroxidase and biotin activity was blocked using
3% H202 and an avidin/biotin blocking kit (Vector Labora-
tories, Burlingame, CA, USA) respectively. Sections were
incubated in 10% (v:v) rabbit serum for 1 hour before
staining with rat anti-mouse F4/80 (1:50 dilution, Santa
Cruz Technology, Santa Cruz, CA, USA). Antibody
binding to sections was detected with rabbit anti-rat
biotin-conjugated secondary antibody and streptavidin-
horseradish peroxidase (HRP) complex (Vector Labora-
tories). Diaminobenzidine substrate (Dako, Glostrup,
Denmark) was used to develop sections and haematoxy-
lin was used as a counterstain.
Image analysis
Immunohistochemistry was viewed with a Leica DMLB
light microscope (Milton Keynes, UK). Analysis across five
random fields of view was performed using the Leica
digital image capture program. Values are expressed as a
percentage of total immunoperoxidase staining.
Osteoclast cell culture and TRAP stain
Bone marrow cells from femurs of WT and IL-10KO mice
were re-suspended in alpha minimum essential medium
(αMEM) supplemented with 10% (v:v) foetal calf serum
(FCS) and seeded at a density of 6.4 × 106 cells/ml in
24-well plates. Following adhesion culture media was
supplemented with macrophage colony-stimulating factor
(MCSF) and receptor activator of NF-κβ ligand (RANKL).
IL-10 and inflammasome inhibitors were added as indi-
cated in figure legends. TRAP-positive cells were detected
after seven days and total RNA isolated from subsequent
analysis.Quantitative real-time PCR (qPCR)
Synovial membranes were dissected from the underpin-
ning cartilage of knee joints [27]. Total RNA was extracted
from samples using TRI Reagent (Sigma-Aldrich) and
cDNA derived from 1 μg of total RNA using a reverse
transcription kit (Primer Design, Southampton, UK) [27].
Gene expression analyses were performed on triplicate
samples with SYBR Green (Invitrogen, Thermo Fisher Sci-
entific, Carlsbad, CA, USA) using an ABI Prism 7900HT
instrument (Applied Biosystems, Thermo Fisher Scientific,
Carlsbad, CA, USA). Details of oligonucleotide primer
sequences are presented in Additional file 1. Data analysis
was performed using the Sequence Detection System
Version 2.3 software (Applied Biosystems).
Enzyme-linked immunosorbent assay (ELISA)
Serum dickkopf-1 (DKK1) was quantified using a com-
mercial enzyme-linked immunosorbent assay (ELISA)
(R&D Systems Inc, Minneapolis, MN, USA) as per the
manufacturer’s instructions.
Statistical analysis
Data was evaluated using the non-parametric Mann-
Whitney U test and an unpaired Student t test. In all
cases, P <0.05 was considered significant.
Results
IL-10KO mice display increased disease severity in
experimental arthritis
In line with an anti-inflammatory role for IL-10 in
experimental arthritis, AIA in IL-10KO mice caused
increased joint swelling and an overall exacerbation of
joint pathology as compared to wild-type (WT) controls
(Figure 1A and B). Evaluation of synovial inflammation
based on synovitis, cellular infiltrate, exudate and joint
damage showed that histopathology was more prolonged
in IL-10KO mice (Figure 1C). Thus, IL-10 acts to pre-
vent long-term subclinical disease and the promotion of
self-limiting synovitis.
IL-10-deficiency is associated with loss of cartilage and
increased bone erosion
To determine the impact of joint inflammation on degen-
erative processes within the inflamed synovium, cartilage
damage was based on a Mankin’s score and quantified as
a percentage loss of safranin-O staining (Figure 2A).
When compared to WT mice, cartilage depletion was
more pronounced in IL-10KO mice at day 28 and 35 post
arthritis induction (Figure 2A). Histology sections from
IL-10KO mice also showed evidence of increased bone
damage and sites of focal bone erosions. While no signifi-
cant difference in the quantification of synovial F4/80
staining was observed in synovial tissue for WT and IL-
10KO mice, an increased localization of F4/80 staining
Figure 1 IL-10KO mice have enhanced and prolonged antigen-induced arthritis (AIA). Disease activity in AIA challenged WT (closed circles)
and IL-10KO (open circles) mice. (A) Joint swelling, (B) arthritic index scores and (C) synovial inflammation are shown. Swelling data reflects the
mean ± SEM of knee diameters (in mm; n = 7-28, *P <0.05). Arthritic index and synovial inflammation values post AIA are presented for individual
joints taken at days 3, 14, 28 and 35 (data is presented as the mean ± SEM, n = 5-7 per time point from a single experiment, *P <0.05, **P <0.01
between WT and IL-10KO groups). IL-10KO, interleukin-10-deficient; WT, wild-type.
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sections from AIA-challenged IL-10KO mice (Figure 2B).
Radiographic assessments of arthritic joints supported this
finding and revealed a more pronounced loss of bone
integrity in IL-10KO mice (Figure 2C). To substantiate an
involvement of IL-10 in bone turnover, the presence of
TRAP-positive osteoclasts was detected (Figure 2D).
Quantification of TRAP stain showed an increase in
TRAP-positive cells in joint sections from IL-10KO mice
(Figure 2D). In accordance, elevated Acp5 (encoding
TRAP) gene expression was also observed in synovial
mRNA from IL-10KO mice (Figure 2D). This was mir-
rored by a systemic increase in the surrogate bone erosion
marker, DKK-1 (Figure 2D).
Focal bone erosions are associated with localized IL-1β
production
To define the mechanisms governing bone damage in IL-
10KO mice, we next considered the inflammatory environ-
ment of the inflamed synovium. Total mRNA was extracted
from the synovium of AIA-challenged mice (taken at day 3
post AIA to reflect the initiation of disease) and cytokine
gene expression compared in IL-10KO and WT mice.
While IL-10KO mice showed no substantive alteration in
synovial Il6 or Tnf over 28 days, there was a twofold
increase in Il1b over that seen in WT mice three days
after arthritis induction, which had resolved by day 28
(Figure 3A). Increased synovial IL-1β expression was
also observed by immunohistochemistry (Figure 3B).
Interleukin-1β protein staining was most prominent in
joint sections from IL-10KO mice at day 28 post AIA
and coincided with the observed elevation in bone ero-
sion. In this regard, IL-1β staining co-localized to areas
of focal bone erosion (Figure 3C). Other IL-1 family
members, including IL-18 and IL-33 have also been
linked with bone turnover [28,29]. Synovial mRNA from
AIA-challenged IL-10KO mice showed no change in
Il18 expression, but a 3.5-fold increase in Il33 as com-
pared to WT controls (Figure 3D). These data highlight
a specific role of IL-1 family members in the destructive
processes of inflammatory arthritis.IL-10 regulates inflammasome expression within the
inflamed synovium
Activation of the inflammasome is required for the gen-
eration of active IL-1β. We therefore examined the syn-
ovial regulation of inflammasome components by IL-10
during arthritis. At day 3 post AIA induction, synovial
Nlrp3, Aim2, Casp1 and Casp12 were all significantly
elevated (approximately two- to threefold) in IL-10KO
mice when compared to WT controls (Figure 4A). In
contrast, Nlrp1, Asc, Rigi, Nod1 and Nod2 remained
largely unaltered from WT mice (Figure 4A). To verify a
link between IL-10 and synovial inflammasome expres-
sion, WT mice were administered (i.a.) with a blocking
anti-IL-10R antibody at the onset of AIA (Figure 4B).
When compared to isotype or vehicle-control treat-
ments, inhibition of IL-10R signaling promoted a three-
to fourfold increase in synovial Nlrp3, Casp1 and
Casp12, while Aim2 showed a trend towards significance
(Figure 4B). Thus, confirming a link between IL-10 and
regulation of the Nlrp3 inflammasome within the in-
flamed synovium.
Regulation of osteoclastogenesis by IL-10 and the
inflammasome
We next sought to provide a link between arthritic bone
erosions and the regulation of the inflammasome. Quan-
titative PCR revealed a positive correlation between
Acp5 and Nlrp3 (r = 0.8173) and Casp1 (r = 0.47) in sam-
ples from IL-10KO mice (Figure 5A). We therefore con-
sidered the involvement of IL-10 and the NLRP3 in an
in vitro MCSF/ RANKL-driven osteoclast differentiation
assay. Consistent with previous studies [13,15], IL-10
blocked osteoclast differentiation by approximately twofold
(Figure 5B). Under these conditions, IL-10 inhibited Acp5
and Ctsk (cathepsin-K, which contributes to osteoclast-
mediated bone resorption) expression (Figure 5B). To
assess the role of the inflammasome in this process, osteo-
clast formation was monitored in the present of cytokine
release inhibitory drug-3 (CRID3) or glibenclamide. CRID3
inhibits NLRP3 and AIM2 by blocking ASC oligomers and
the activation of caspase 1 [30], while glibenclamide is an
Figure 2 Bone erosions are augmented in the IL-10KO joints following antigen-induced arthritis (AIA). (A) Mankin’s score (indicating
severity of cartilage damage) (left) and percentage of cartilage degradation of mouse joints (right) at day 28 and 35 post arthritis induction
(mean ± SEM, n = 6-7 mice/time point from a single experiment; P <0.05 between WT (closed circles) and IL-10KO (open circles) groups).
(B) Representative Haematoxylin and ‘safranin-O Green-stained parasagittal joint sections (left) taken on day 35 are shown for WT and IL-10KO
mice. The star indicates cartilage degradation and diamond shows bone erosion (scale bar: 100 μm). Representative F4/80 staining (right) adjacent
to bone erosions in joint sections (scale bar: 500 μm) from IL-10KO mice three days post AIA (right). (C) Radiographic scoring (left) and representative
radiographic images (right) of the joints of WT and IL-10KO mice 28 days post arthritis induction. Representative images are presented from a
single experiment using six to eight mice per mouse strain. (D) WT and IL-10KO joints were stained for TRAP positivity (left) on day 28 post AIA
(scale bar: 200 μM) and quantified by computer analysis (top middle) (n = 3-5 mice), and expression in the joints of osteoclast marker; Acp6 was
determined by qPCR and made relative to the values for 18S ribosomal RNA (n = 9 mice) (top right). Serum DKK1 (bottom) was detected using
commercial ELISA in samples obtained from challenged WT and IL-10KO mice (n = 6-7 mice/mouse strain, *P <0.05). DKK1, dickkopf-1; ELISA,
enzyme-linked immunosorbent assay; IL-10KO, interleukin-10-deficient; qPCR, quantitative real-time PCR; TRAP, tartrate-resistant alkaline
phosphatase; WT, wild-type.
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maturation of caspase 1 and pro-IL-1β through NLRP3
[31]. Using myeloid progenitors from IL-10KO mice,
addition of CRID3 or glibenclamide significantly reduced
osteoclast numbers and blocked generation of TRAP-
positive cells (Figure 5C). These data support a role for
NLRP3 in governing bone turnover and erosion.
Discussion
Innate sensing mechanisms were traditionally linked with
the recognition of bacterial, fungal and viral infections.This viewpoint has, however, changed and many act as
sensors of both endogenous and exogenous danger signals
[32-34]. Members of the NLR family are intrinsic to
caspase-activating complexes termed the inflammasome.
These receptors recognize certain infectious pathogens,
particles (for example, microcrystals), metabolic anomalies
(for example, hyperglycaemia, ATP) and chemicals, and
contribute to the pathology of various autoinflammatory
diseases [32]. This has led to the novel application of
drugs that target IL-1β (for example, anakinra, canakinu-
mab and rilonacept) in conditions such as periodic fever
Figure 3 Augmented IL-1β in the IL-10KO mice following antigen-induced arthritis (AIA). (A) Expression of inflammatory cytokines; Il6, Tnf
and Il1b were examined in the synovial mRNA of WT (closed circles) and IL-10KO (open circles) mice 3 and 28 days after AIA induction and made
relative to the values for 18S ribosomal RNA (n = 4-7, *P <0.05). (B) Representative immunohistochemistry (left) and computer-quantified scoring
(right) of IL-1β staining in joint sections (scale bar: 100 μm) for WT and IL-10KO joints. Results show individual joints taken over the course of
disease in AIA-challenged mice (n = 3-6). (C) Representative immunohistochemical staining for areas of focal IL-1β secretion in IL-10KO bone
28 days post AIA (scale bar: 300 μm). (D) Il18 and Il33 were examined in synovial mRNA from WT and IL-10KO mice taken three days after AIA
induction. Values were made relative to 18S ribosomal RNA (n = 5-11, ***P <0.001). IL-10KO, interleukin-10-deficient; WT, wild-type.
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arthritis where conventional anti-inflammatory drugs fail to
provide long-lasting relief [35]. Here, we show that IL-10
negatively regulates the expression of NLRP3 inflamma-
some components within the inflamed synovium of ex-
perimental arthritis and provide a link to degenerative
bone erosion.
Several lines of evidence support an involvement of the
inflammasome in inflammatory and degenerative arthritis.
While NLRP3 is expressed in RA and OA synovium
[36,37] it is difficult to comment on the functional signifi-
cance of these findings as quantification of transcript levels
provide minimal information on inflammasome activity.
An involvement of the inflammasome in joint pathology is
illustrated by studies of calcium crystals, which accumulate
through biomechanical stress or altered mechanisms of cal-
cification. Here, the ectopic deposition of hydroxyapatite
crystals in synovial fluids from osteoarthritis patients is as-
sociated with disease progression [38]. Hydroxyapatite crys-
tals activate the NLRP3 inflammasome to promote IL-1β
and IL-18 release by lipopolysaccharide (LPS)-primedmacrophages [24]. Studies in an air pouch model of syno-
vitis also confirmed the activation of NLRP3/ASC/caspase
1 by hydroxyapatite crystals and supported a role in con-
trolling neutrophil infiltration [24]. Analysis of synovial in-
flammation in AIA-challenged ASC-KO mice showed
reduced disease severity [39]. This response was not, how-
ever, seen in NLRP3-KO and caspase1-KO mice, where
both genotypes showed similar pathology to that observed
in WT controls [39]. These results are consistent with
our own, where we see similar disease pathology be-
tween the WT and IL-10KO mice at these early time
points. We now show that at the later stages of inflam-
matory arthritis, in the absence of IL-10, joint inflamma-
tion results in a temporal increase in synovial IL-1β,
which corresponds with enhanced pathology and co-
localization to areas rich in F4/80-postive cells that clus-
ter at sites of focal bone erosion. Such changes in IL-1β
may reflect the capacity of IL-10 to inhibit TLR control
of Il1β (pro-IL-1β) and the expression of NLRP3 inflam-
masome components. At this stage we are, however, un-
able to ascertain what inflammatory events (for example,
Figure 4 IL-10 modulates specific inflammasome component expression during antigen-induced arthritis (AIA). (A) Expression of
inflammasome components; Nlrp3, Aim2, Casp1, Casp12, Nlrp1, Asc, Rigi, Nod1 and Nod2 were examined in synovial mRNA of WT (closed circles)
and IL-10KO (open circles) mice three days after AIA induction. Values are relative to 18S ribosomal RNA (n = 5-9, *P <0.05). (B) Changes in Nlrp3,
Aim2, Casp1 and Casp12 in WT joint sections treated without/with intra-articular-administrated anti-IL-10R or isotype control antibody at the onset
of AIA. Values are presented for individual joints taken at day 3 post AIA and are relative to 18S ribosomal RNA (n = 3-15, *P <0.05). IL-10KO,
interleukin-10-deficient; WT, wild-type.
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of these inflammasome genes.
Our results implicate the involvement of the inflam-
masome in osteoclastogenesis, with IL-10 deficiency
causing an increase in both synovial IL-1β and IL-33
expression, but not IL-18. Interleukin-1β is considered
pro-osteoclastogenic and drives an imbalance in chon-
drocyte responses through regulation of prostanoids,
nitric oxide and other free radicals, and the induction of
degradative enzymes that impact collagen and proteo-
glycan turnover [40,41]. In contrast, IL-33 and IL-18 are
considered anti-osteoclastogenic and protect against
tumour necrosis factor alpha (TNFα)-mediated bone
loss [42,43]. Thus, IL-33 often opposes the activities of
IL-1β, which raises a question about the regulation of
these cytokines by the NLRP3/caspase 1 system. While
pro-IL-1β and pro-IL-18 are processed by caspase 1 into
mature active forms, full-length IL-33 is already bio-
logically active and is released as a consequence of cell
damage [44]. Further processing by caspase 1 causes in-
activation of IL-33 [44,45]. IL-33 is also modified by the
activity of elastase and cathepsin G, which are secreted
by infiltrating neutrophils and enhance IL-33 bioactivity
[46]. Here, IL-33 acts as an endogenous danger signal
(alarmin), which alerts innate immune cells to sites of
infection or injury. Thus, the elevated expression of
Il33 in IL-10KO mice may simply reflect the overall in-
crease in synovial inflammation. Moreover, the blockadeof osteoclastogenesis by CRID3 and glibenclamide
suggests a role for caspase 1 in bone turnover. Targeting
the inflammasome may therefore benefit joint patholo-
gies allied with IL-1β production, such as OA, Muckle-
Wells syndrome (an autoinflammatory disorder linked
with mutations in NLRP3) and gout [20,35,47,48]. Such
an approach may provide an added benefit over
traditional biologic interventions including anakinra,
which in clinical trials of OA offered no improvement in
symptoms [49]. To provide preclinical evidence to
support this notion, attempts were made to treat AIA-
challenged IL-10KO mice (i.a.) with either CRID3 or glib-
enclamide. However, administration (i.a.) of vehicle alone
as a control promoted a robust inflammatory response,
which prevented the direct investigation of this in vivo.
Our results indicate that IL-10 has the capacity to
inhibit expression of NLRP3 and certain components of
the inflammasome. Here, neutralization of IL-10 recep-
tor signaling in WT mice enhanced synovial Nlrp3 and
Casp1 expression and addition of endogenous IL-10
inhibited the formation of TRAP+ osteoclasts in vitro.
Significantly, human trials with recombinant IL-10
showed no improvement in disease activity [50], while
IL-10 responses in synovial macrophages from RA
patients appear dysregulated [51]. Such alterations in
IL-10 responsiveness results in a loss of its anti-
inflammatory properties and a concomitant acquisition
of interferon-gamma (IFNγ)-like activities [51].
Figure 5 IL-10 modulates inflammasome-driven osteoclastogenesis ex vivo and during antigen-induced arthritis (AIA). (A) Correlation of
Nlrp3 and Casp1 with Acp5 in mRNA derived from the synovium of IL-10KO mice at day 28 post AIA. Values are relative to 18S ribosomal RNA (n = 8-9).
(B) Bone marrow cells from WT mice were cultured with MCSF in the presence (closed and open circles, left, black and grey bars, right) or absence
(white bars, right) of RANKL and IL-10 (30 ng/ml) as indicated (open circles, left, grey bars, right). Values are derived from five independent fields of view
from an experiment performed in triplicate. Representative pictures of cells treated with MCSF (left), MCSF and RANKL (middle) and MCSF, RANKL and
IL-10 (right). Data was accumulated from two separate experiments. (Scale bar: 300 μm.) Expression of osteoclast markers; Acp5 and Ctsk, were
determined by qPCR and compared against 18S ribosomal RNA. (C) Bone marrow cells from IL-10KO mice were cultured RANKL and MCSF. Osteoclast
formation was determined in the presence of vehicle alone (closed circles), 30 μM of CRID3 (open circles, left) or 25 μg/ml glibenclamide (open circles,
right). Data is representative of three experiments performed in triplicate (*P <0.05). Scale bar 300 μm. CRID3, cytokine release inhibitory drug-3;
IL-10KO, interleukin-10-deficient; MCSF, macrophage colony-stimulating factor; qPCR, quantitative real-time PCR; RANKL, receptor activator of nuclear
factor-κβ ligand; WT, wild-type.
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Our studies implicate a link between IL-10 and expression
of the NLRP3 inflammasome within the inflamed syno-
vium, and advocate a role for IL-10 and inflammasome ac-
tivation in governing osteoclastogenesis and bone erosion.
With advances in synovial histopathology taking centre
stage in clinical practice [2], monitoring IL-10 or inflam-
masome activities within the inflamed joints of patients
with early RA may prove valuable as a predictor of disease
activity or bone erosions, and may help tailor the design
of novel treatments for defined patient groups.
Additional file
Additional file 1: Oligonucleotide primer sequences for real-time
PCR. Oligonucleotide primer sequences for each of the inflammatory
mediators measured in the study. All sequences are listed in the 5′-3′
direction.
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